Beijing-based private equity firm Huagai Capital has led a $146.6-million round in China’s HaiHe Biopharma, which is engaged in the discovery, development and commercialisation of drugs for cancer treatment, according to an official release.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
